**The April 2026 DOJ/DEA order moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, following President Trump’s December 2025 executive order directing expedited rulemaking.** This partial rescheduling provides immediate regulatory relief for qualifying medical operators and research while preserving controls on illicit trafficking. A separate expedited administrative hearing on broader rescheduling of all marijuana to Schedule III opened June 29, 2026, at DEA headquarters and was scheduled to conclude by July 15. The proceeding gathers evidence on medical value and abuse potential to support or refine the 2024 notice of proposed rulemaking. Post-hearing, an administrative law judge recommendation and final agency action will determine full implementation timelines, subject to potential legal challenges such as those in the D.C. Circuit. Trader probabilities reflect the pace of these administrative steps, any delays in the final rule, and structural barriers like inter-agency coordination or court review before a complete shift from Schedule I occurs.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui$791,987 Vol.
September 30
14%
December 31
28%
$791,987 Vol.
September 30
14%
December 31
28%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Pasar Dibuka: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...**The April 2026 DOJ/DEA order moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, following President Trump’s December 2025 executive order directing expedited rulemaking.** This partial rescheduling provides immediate regulatory relief for qualifying medical operators and research while preserving controls on illicit trafficking. A separate expedited administrative hearing on broader rescheduling of all marijuana to Schedule III opened June 29, 2026, at DEA headquarters and was scheduled to conclude by July 15. The proceeding gathers evidence on medical value and abuse potential to support or refine the 2024 notice of proposed rulemaking. Post-hearing, an administrative law judge recommendation and final agency action will determine full implementation timelines, subject to potential legal challenges such as those in the D.C. Circuit. Trader probabilities reflect the pace of these administrative steps, any delays in the final rule, and structural barriers like inter-agency coordination or court review before a complete shift from Schedule I occurs.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui



Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan